EUVIMEDEUVIMED entdecken
Crossref

Late-stage functionalization with strain-release warheads enables tunable covalent inhibition

Zachary P Shultz iD, Ansar Lee-Sam iD, Yun-Pu Chang iD, Luxin Sun iD, Dylan Grassie iD, Alessio Gabellini, Kyle Pedretty iD, Thomas Scattolin iD, Victoria Izumi iD, Bin Fang iD, Samer Sansil iD, Ramu Kakumanu iD und 6 weitere

Science · 23.07.2026 · 393 (6809) · 408-416

DOI: 10.1126/science.adx7219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 23.07.2026. Verfasst von Zachary P Shultz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Cysteine, Drug Design, Proteins, Sulfur. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Covalent inhibition continues to gain momentum as a strategy for selective protein modulation in both therapeutic and chemical biology contexts. Covalent reactive groups (CRGs) typically engage nucleophilic residues such as cysteine, resulting in targeted protein inactivation. However, common electrophiles such as acrylamides often suffer from nonselective reactivity, leading to off-target effects and toxicity. To overcome these limitations, we developed a modular sulfur(IV) reagent platform for the mild, late-stage installation of sulfonyl- and sulfonimidoyl-bicyclobutane motifs with complete cysteine selectivity. This methodology enables access to diverse sulfur(VI) CRGs with tunable strain-release reactivity. Incorporation into US Food and Drug Administration–approved covalent inhibitors demonstrated effective bioisosteric replacement of acrylamides and the potential of strain-release CRGs for selective protein targeting. Preclinical studies in mice have validated this approach, highlighting its promise for next-generation covalent drug design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CysteineDrug DesignProteinsSulfurAnimalsMiceAcrylamidesBioisosterism

Substanzen

AcrylamidesCysteineProteinsSulfur

Autor:innen und Institutionen

  • Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Department of Chemistry, University of South Florida, Tampa, FL, USA.
  • Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Cancer Pharmacokinetics and Pharmacodynamics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, FL, USA.

ORCID-Profile: Zachary P Shultz, Ansar Lee-Sam, Yun-Pu Chang, Luxin Sun, Dylan Grassie, Kyle Pedretty, Thomas Scattolin, Victoria Izumi, Bin Fang, Samer Sansil, Ramu Kakumanu, Lukasz Wojtas, John Koomen, Ernst Schönbrunn, Andrii Monastyrskyi, Derek Duckett, Justin M Lopchuk

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • National Institute of General Medical Sciences

Zitieren

APA

Shultz, Z. P., Lee-Sam, A., Chang, Y. P., Sun, L., Grassie, D., Gabellini, A., Pedretty, K., Scattolin, T., Izumi, V., Fang, B., Sansil, S., Kakumanu, R., Wojtas, L., Koomen, J., Schönbrunn, E., Monastyrskyi, A., Duckett, D., & Lopchuk, J. M. (2026). Late-stage functionalization with strain-release warheads enables tunable covalent inhibition. Science, 393(6809), 408-416. https://doi.org/10.1126/science.adx7219

Vancouver

Shultz ZP, Lee-Sam A, Chang YP, Sun L, Grassie D, Gabellini A, et al. Late-stage functionalization with strain-release warheads enables tunable covalent inhibition. Science. 2026;393(6809):408-416. doi:10.1126/science.adx7219

BibTeX
@article{Shultz2026,
  author = {Shultz, Zachary P and Lee-Sam, Ansar and Chang, Yun-Pu and Sun, Luxin and Grassie, Dylan and Gabellini, Alessio and Pedretty, Kyle and Scattolin, Thomas and Izumi, Victoria and Fang, Bin and Sansil, Samer and Kakumanu, Ramu and Wojtas, Lukasz and Koomen, John and Schönbrunn, Ernst and Monastyrskyi, Andrii and Duckett, Derek and Lopchuk, Justin M},
  title = {Late-stage functionalization with strain-release warheads enables tunable covalent inhibition},
  journal = {Science},
  year = {2026},
  volume = {393},
  number = {6809},
  pages = {408--416},
  doi = {10.1126/science.adx7219}
}
Kostenlos starten →